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Abstract
Background: Human tuberculosis caused by Mycobacterium bovis is believed to be frequent in developing countries.
Transmission is usually through ingestion of unpasteurized dairy products, although airborne contagion is possible.
Disease caused by M. tuberculosis or M. bovis is clinically indistinguishable from each other. The aim of this study was
to determine the factors associated with M. bovis disease.
Methods: Retrospective analysis of all culture-positive cases of M. bovis and M. tuberculosis from 2000 to 2015, in a
Mexican tertiary-care centre. Sociodemographic, clinical, and radiographic data from medical records were compared.
Disease site was classified as pulmonary, extrapulmonary, or pulmonary and extrapulmonary, based on cultures.
Results: We evaluated 533 cases, 372 (69.7 %) of which were caused by M. tuberculosis and 161 (30.2 %) by M. bovis.
Characteristics associated with M. bovis disease were: younger age (aOR 0.97, 95 % CI 0.95–0.98), glucocorticoid use (aOR
2.27, 95 % CI 1.42–3.63), and extrapulmonary disease (aOR 1.80, 95 % CI 1.21–2.69). M. tuberculosis was associated with
lower socioeconomic status (aOR 0.52, 95 % CI 0.28–0.97). When we analysed only pulmonary cases, younger
age (aOR 0.97, 95 % CI 0.96–0.99), glucocorticoid use (aOR 2.41, 95 % CI 1.30–4.46), and smoking (aOR 1.94,
CI 95 % 1.15–3.27) were associated with M. bovis. Both groups showed similar proportions of direct microscopy smear
results (respiratory samples) and chest X-ray cavitations.
Conclusions: Younger age, glucocorticoid use, and extrapulmonary disease were associated with M. bovis as the causative
agent of tuberculosis in a group of patients from a tertiary care centre in a country where bovine tuberculosis is endemic.
Further studies must be conducted in the general population to determine pathogen-specific associated factors and
outcomes.
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Background
Mycobacterium bovis, a member of the Mycobacterium
tuberculosis complex, causes tuberculosis (TB) in cattle
and a wide range of mammals including humans, although
to a lesser extent than Mycobacterium tuberculosis. The
implementation of bovine TB (BTB) eradication programs
and universal pasteurization of dairy products in devel-
oped countries has reduced the disease in these regions,
and thus clinicians often overlook the possibility of human
TB caused by M. bovis [1, 2]. Conversely, in developing
countries, M. bovis disease is likely to be still frequent but
underreported because of reliance on laboratory tech-
niques that are insufficient to identify the different species
within the M. tuberculosis complex (i.e., direct smear
microscopy, GeneXpert molecular testing, or culture with-
out species-level identification) [3].
Disease caused by either M. bovis or M. tuberculosis is
considered clinically and radiologically indistinguishable
from each other [4]. Nevertheless, M. bovis is naturally
resistant to pyrazinamide, an essential component of the
first-line anti-TB drug regimen [5]. Hence, prompt and
correct identification of the causative agent can have im-
portant implications for patient outcomes [6].
The main route of transmission is through consump-
tion of unpasteurized dairy products, and thus M. bovis
usually presents as extrapulmonary disease [1]. Before
genetic investigations were common, human-to-human
spread via aerosolized particles was a subject of contro-
versy [7]. However, recent reports from hospital and
community outbreaks indicate that this type of transmis-
sion is feasible [8, 9]. Still, irrespective of its route of
transmission, pulmonary disease accounts for a sizeable
proportion of all M. bovis cases in developed countries,
and perhaps much more in endemic regions [10].
Recent reports underscore the importance of understand-
ing the epidemiology of M. bovis disease [11, 12]. Younger
age, HIV coinfection, and other immunosuppressive condi-
tions are some of the described associated factors [11]. Of
note, a connection with Mexico (in the form of country of
birth, contact with family members, or consumption of
unpasteurized dairy products) has been the most frequently
reported risk factor in research conducted in the United
States [6, 10, 11, 13–15]. In this context, the aim of this
study was to describe the sociodemographic, epidemio-
logical, and clinical characteristics, and to determine the




This study was conducted at a 230-bed, national referral
centre for adult patients with complex medical and
surgical problems, located in Mexico City with approxi-
mately 6000 discharges annually. This centre’s laboratory
of clinical microbiology maintains a database containing
information on all positive mycobacterial cultures. We
searched this database to identify all patients with a
positive culture for M. tuberculosis or M. bovis who were
admitted to the hospital during the period 2000–2015.
Variables and definitions
We reviewed the medical records of the identified
patients and retrieved variables of interest using a spe-
cially designed case report form. Patients with incom-
plete or missing medical records were excluded from the
study. Socioeconomic status was evaluated based on the
hospital’s 7-point score assigned by a social worker upon
admission. This scale is based on family income, occupa-
tion, educational level, number of house residents, number
of school-age children in the family, construction material
of the house, ownership of current residence, setting (urban
or rural), and availability of services (electricity, paved
roads, running water, and sewage) [16]. We defined low
socioeconomic status as a grade <2. Also, we categorized
patients as residents of a non-accredited zone for BTB
eradication by the United States Department of Agri-
culture using data provided by the Servicio Nacional
de Sanidad Inocuidad y Calidad Agroalimentaria
(SENASICA). This is the government office in charge
of monitoring BTB control in Mexico [17]. Pulmonary
disease was defined as a positive culture from spu-
tum, bronchoalveolar lavage, endotracheal aspirate,
gastric aspirate, lung and pleural biopsy, pleural fluid,
or intrathoracic lymph nodes. Extrapulmonary disease
was defined as a positive culture from any other ana-
tomical site. Glucocorticoid use was defined as ≥ 15 mg of
prednisone or its equivalent for more than one month in
the year previous to TB diagnosis [18]. Multidrug resist-
ance (MDR) was defined as resistance to at least both
rifampicin and isoniazid.
Microbiology procedures
Samples for mycobacteria identification were digested,
decontaminated by the NALC-NaOH method [19, 20],
and inoculated in both Löwenstein-Jensen medium and
MGIT tubes (Becton-Dickinson, Sparks, MA), according
to the manufacturer’s specifications. Samples labelled as
biopsies were additionally inoculated in Stonebrink
culture medium. All positive cultures were further iden-
tified by DNA probe (Accuprobe, San Diego, CA). Dur-
ing the study period, all M. tuberculosis complex isolates
were identified to the species level. We defined M. bovis
as a positive culture with dysgonic growth and biochem-
ical tests results (niacin production, nitrate reduction,
thiophen-2-carboxylic acid anhydride susceptibility, and
pyrazinamidase deamidation) typical of this species, and
M. tuberculosis as a positive culture with eugonic growth
and compatible biochemical test results (niacin production,
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nitrate reductase positive test and heat-stable catalase
activity) [21]. Additionally, both M. bovis and M. tu-
berculosis identification was confirmed by spoligotyp-
ing from 2000 to 2013 and by the GenoType MTBC
(Hain Lifescience GmbH, Nehren, Germany) test from
2013 to 2015 [22, 23]. Susceptibility testing for rifam-
picin, streptomycin, isoniazid, and ethambutol was
performed using the radiometric BACTEC 460 or the
BACTEC 960 culture system (Becton-Dickinson,
Sparks, MA) [24].
Statistical methods
The characteristics of M. bovis and M. tuberculosis cases
were compared by univariate analysis using the χ2 test,
Fisher’s exact test, Student’s unpaired t-test, and the
Mann–Whitney U test, as appropriate. To determine
characteristics associated with M. bovis as compared
with M. tuberculosis we used unconditional logistic
regression. The models were validated by evaluating
their suitability, model specificity and multicollinearity.
Variables included in the models were those with p-values
<0.2 in the univariate analysis or with biological
plausibility. The final model was achieved using a
hierarchical backward elimination approach. The vari-
able association was expressed as adjusted odds ratio
(aOR) at 95 % confidence interval (CI). All statistical
analyses were performed using STATA 11.0 software
(StataCorp, College Station, TX).
Results
We identified 610 patients with culture-positive TB
identified to the species level for the period 2000–2015.
We excluded 77 (61M. tuberculosis, 16M. bovis)
because of missing or incomplete records. Of the
remaining 533 cases, 372 (69.7 %) were identified as M.
tuberculosis and 161 (30.2 %) as M. bovis. Twenty-nine
percent (155/533) of these cases were diagnosed from
2000 to 2004, 27.4 % (146/533) from 2005 to 2009
and 43.5 % (232/533) from 2010 to 2015. The propor-
tion of M. bovis isolates from each period were
24.5 % (38/155), 32.8 % (48/146) and 32.3 % (75/232),
respectively.
Sociodemographic characteristics and comorbidities
Fifty-six percent (303/533) of the cases were male and
22.8 % (122/533) occurred in presence of HIV co-infection.
The univariate analysis indicated that younger age, connect-
ive tissue disease, and glucocorticoid use were more fre-
quent among patients with M. bovis disease. Conversely,
patients with M. tuberculosis presented diabetes mellitus
diagnosis more frequently. History of consumption of
unpasteurized dairy products was often missing from clin-
ical records as it was reported in 5/15 (33.3 %) of the M.
bovis cases and 10/27 (37 %) of M. tuberculosis (p = 0.81).
Neither residency in a non-accredited zone for BTB eradi-
cation, nor positive HIV status were significantly different
among M. bovis cases (Table 1).
Clinical and microbiological characteristics
Among the 533 patients, MDR was detected in the first
cultured isolates of seven patients. Six of these were M.
tuberculosis (4 pulmonary, 2 extrapulmonary), and one
was M. bovis (pulmonary). The univariate analysis
showed differences between the proportions of M. bovis
and M. tuberculosis cases concerning disease site,
presenting symptoms, and mean tuberculin skin test
(TST) induration. Extrapulmonary disease accounted for
41.6 % of M. bovis cases, and 30.1 % of M. tuberculosis
(p = 0.01). Pulmonary disease was observed in 36 % of
M. bovis, and 52.6 % of M. tuberculosis (p < 0.001). Lim-
iting the analysis to patients with extrapulmonary dis-
ease only, M. bovis presented with abdominal TB in
32.8 % of the cases, compared with 10.7 % for M. tuber-
culosis (p < 0.001). No differences were observed with
respect to disease site when limiting the analysis to
patients with both pulmonary and extrapulmonary dis-
ease. Regarding clinical presentation, M. bovis patients
more frequently reported fever and gastrointestinal
symptoms, whereas M. tuberculosis cases reported more
respiratory symptoms. The mean TST induration among
M. bovis cases was 9.6 mm, compared with 14 mm in
M. tuberculosis cases (p = 0.02; Table 2). We observed
no difference between both species regarding in-
hospital, 90-day mortality (20/161; 12.4 %M. bovis vs.
51/372; 13.7 %M. tuberculosis).
Characteristics of pulmonary disease
When we restricted the analysis to cases with pul-
monary involvement, younger age, smoking, gluco-
corticoid use, and normal and miliary chest X-ray
(CXR) appearance were associated with M. bovis. In
contrast, working in a farm, low socioeconomic sta-
tus, presenting with cough, and nodule on CXR were
more frequent among M. tuberculosis cases. Direct
microscopy smear results of respiratory samples were
similar for both groups (Table 3).
Multivariate analysis
In the overall analysis, younger age (aOR 0.97; 95 %
CI 0.95–0.98), glucocorticoid use (aOR 2.27; 134 95 %
CI 1.42–3.63), extrapulmonary disease (aOR 1.80; CI
1.21–2.69) and higher socioeconomic status (aOR 0.52;
95 % CI 0.28–0.97) were independently associated with M.
bovis disease. When we restricted the analysis to pulmon-
ary cases, younger age (aOR 0.97; 95 % CI 0.96–0.99),
glucocorticoid use (aOR 2.41; 95 % CI 1.30–4.46), and
smoking (aOR 1.94; 95 % CI 1.15–3.27) were independ-
ently associated with M. bovis (Table 4).
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Discussion
In this study, conducted in a country considered of spor-
adic occurrence of BTB, we observed sociodemographic,
clinical, and radiographic differences between M. bovis
and M. tuberculosis cases. Younger age, glucocorticoid
use, and extrapulmonary disease were associated with
M. bovis. Cigarette smoking was additionally associated
with M. bovis among the pulmonary cases. M. tubercu-
losis was associated with lower socioeconomic status.
We found a higher proportion of M. bovis in comparison
to similar hospital-based studies. We previously reported
this fact in a study encompassing local and referred samples
from other hospitals in the region [3, 25, 26]. Also, we re-
ported an uprising tendency in the proportion of M. bovis
isolates through time. This may be attributed to the larger
study period, and a higher proportion of immunosup-
pressed population along with the poor control of BTB in
the region, especially among dairy farms and artisan dairy
products retail [3, 27].
In this study, M. bovis cases were significantly younger;
this was true for all clinical presentations even after
adjustment with comorbidities that may present in the
younger population such as connective tissue diseases or
hematologic malignancies. Contrary to what others have
suggested, this may indicate a shorter latency period for
M. bovis disease [12, 28]. However, it is also possible that
unpasteurized dairy consumption may be more frequent
at younger ages; unfortunately, this variable was often
missing from the clinical record, and thus it was impossible
for us to ascertain this fact. Studies accurately exploring the
time of exposure and unpasteurized dairy consumption are
needed in order to confirm these hypotheses.
A large proportion of our study population was receiv-
ing glucocorticoids in the year previous to TB diagnosis;
this is explained by the fact that our hospital treats a
large population of patients with autoimmune diseases.
Glucocorticoids modify the cellular response, a critical
component for the containment of TB infection, and
have been previously described as a risk factor for disease
reactivation [29, 30]. In this study, glucocorticoids were
associated with M. bovis, suggesting that immunosuppres-
sion may favour M. bovis disease. In fact, tuberculin skin
Table 1 Sociodemographic characteristics and comorbidities of patients with tuberculosis caused by Mycobacterium bovis or







Age, years, median (IQR) 38 (29–52) 49 (33–64) <0.001b
Sex (female) 66/161 (40.9) 164/372 (44) 0.5
Healthcare worker 5/151 (3.3) 19/360 (5.2) 0.33
Farm worker 5/151 (3.3) 26/360 (7.2) 0.09
Low socioeconomic status 17/161 (10.5) 62/372 (16.6) 0.068
BCG-vaccinated 82/118 (69.4) 179/261 (68.5) 0.86
Contact with TB-infected people 18/139 (12.9) 67/335 (20) 0.069
Resides in a non-accredited zone for bovine-TB eradicationc 140/159 (88) 303/370 (81.8) 0.078
Alcohol intake≥ 40 g/day 9/152 (5.9) 36/354 (10.1) 0.12
Smoker (present) 71/153 (46.4) 147/356 (41.2) 0.28
HIV coinfection 43/161 (26.7) 79/372 (21.2) 0.16
CD4 count ≤200 cells/mm3 31/35 (88.5) 60/67 (89.5) 0.87
Diabetes mellitus 23/161 (14.2) 84/372 (22.5) 0.028
Connective tissue diseased 29/161 (18) 43/372 (11.5) 0.045
Solid organ transplant recipient 4/161 (2.4) 8/372 (2.1) 0.81
Charlson comorbidity index ≥3 72/161 (44.7) 150/372 (40.3) 0.34
Previous TB 2/161 (1.2) 14/372 (3.7) 0.11
Glucocorticoid usee 46/161 (28.5) 54/372 (14.5) <0.001
Data are n/N (%) of cases, unless otherwise indicated. n values across categories might be less than the counts in the column headings due to missing data
IQR Interquartile range, TB Tuberculosis, HIV Human immunodeficiency virus, BCG Bacillus Calmette-Guérin
ap values were determined by the χ2 test
bp value was determined by Student’s t-test
cAs determined by SENASICA
dSystemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, dermatomyositis, ankylosing spondylitis, mixed connective tissue disease,
systemic sclerosis
e ≥ 15 mg/d of prednisone or equivalent dose of steroids for 1 month or more in the year prior to TB diagnosis
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Table 2 Clinical and microbiologic characteristics of patients with tuberculosis caused by Mycobacterium bovis or Mycobacterium







Anatomical site of isolation
Pulmonary 58/161 (36) 196/372 (52.6) <0.001
Extrapulmonary 67/161 (41.6) 112/372 (30.1) 0.01
Pulmonary and Extrapulmonary 36/161 (22.3) 64/372 (17.2) 0.16
Primary site of isolation (Restricted to pulmonary cases with and extrapulmonary involvements casesb)
Abdominalc 7/36 (19.4) 22/64 (34.3) 0.11
Genitourinary 16/36 (44.4) 22/64 (34.3) 0.31
Central Nervous System 10/36 (27.7) 9/64 (14) 0.093
Lymph node 0/36 (0) 1/64 (1.5) –
Skin, joint, bone, and soft tissue 3/36 (8.3) 2/64 (3.1) 0.25
Blood, bone marrow, liver, and spleen 0/36 (0) 8/64 (12.5) –
Primary site of isolation (Restricted to extrapulmonary casesd)
Abdominalc 22/67 (32.8) 12/112 (10.7) <0.001
Genitourinary 9/67 (13.4) 26/112 (23.2) 0.11
Central Nervous System 14/67 (20.9) 17/112 (15.1) 0.32
Lymph node 15/67 (22.3) 37/112 (33) 0.12
Skin, joint, bone, and soft tissue 4/67 (5.9) 13/112 (11.6) 0.21
Blood, bone marrow, liver, and spleen 3/67 (4.4) 7/112 (6.2) 0.61
Primary site of isolation (Restricted to pulmonary cases with and extrapulmonary involvement casesd)
Abdominalc 7/36 (19.4) 22/64 (34.3) 0.11
Genitourinary 16/36 (44.4) 22/64 (34.3) 0.31
Central Nervous System 10/36 (27.7) 9/64 (14) 0.093
Lymph node 0/36 (0) 1/64 (1.5) –
Skin, joint, bone, and soft tissue 3/36 (8.3) 2/64 (3.1) 0.25
Blood, bone marrow, liver, and spleen 0/36 (0) 8/64 (12.5) –
Symptom onset to diagnosis, days, median (IQR) 63 (32–154) 90 (34–197) 0.089e
Presenting symptoms
Fever 127/159 (79.8) 254/364 (69.7) 0.019
Weight loss 72/159 (45.2) 181/364 (49.7) 0.38
Cough 60/159 (37.7) 195/364 (53.5) 0.001
Haemoptysis 5/159 (3.1) 29/364 (7.9) 0.039
Gastrointestinalf 71/159 (44.6) 117/364 (32.3) 0.007
Neurological 30/159 (18.8) 63/364 (17.3) 0.67
Genitourinary 10/159 (6.2) 29/364 (7.9) 0.49
Primary multidrug resistanceg 1/161 (0.6) 6/372 (1.6) 0.35
Mean TST induration, mm, (IQR) 9.6 (0–18) 14 (0–25) 0.02e
≥5 mm 30/76 (39.4) 91/172 (52.9) 0.051
≥10 mm 29/76 (38.1) 91/172 (52.9) 0.032
≥15 mm 23/76 (30.2) 79/172 (45.9) 0.021
Data are n/N (%) of cases, unless otherwise indicated. n values across categories might be less than the counts in the column headings due to missing data
IQR Interquartile range, TST tuberculin skin test
ap values were determined by the two-sample test of proportion or the χ2 test, as appropriate
bRestricted to cases with extrapulmonary disease only
cGastrointestinal, peritoneal, and faecal samples
dRestricted to cases with both pulmonary and extrapulmonary disease
ep value was determined by the Mann–Whitney U test
fDiarrhoea, vomiting, and abdominal pain
gResistance to at least both isoniazid and rifampicin
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Table 3 Clinical and radiographic characteristics of patients with pulmonarya tuberculosis caused by Mycobacterium bovis or







Age, years, median (IQR) 39 (30–51) 46 (30–64) 0.0053c
Sex (female) 33/94 (35.1) 99/260 (38) 0.61
Healthcare worker 3/88 (3.4) 15/255 (5.8) 0.37
Farm worker 2/88 (2.2) 22/255 (8.6) 0.044
Low socioeconomic status 9/94 (9.5) 49/260 (18.8) 0.037
BCG-vaccinated 42/63 (66.6) 130/186 (69.8) 0.63
Contact with TB-infected people 11/80 (13.7) 48/235 (20.4) 0.18
Resides in high-prevalence region of bovine TBd 83/93 (89.2) 209/259 (80.6) 0.06
Alcohol intake≥ 40 g/dayay 5/89 (5.6) 30/251 (11.9) 0.09
Unpasteurized dairy products consumption 2/10 (20) 8/17 (47) 0.16
Smoker (present) 50/89 (56.1) 103/253 (40.7) 0.012
HIV coinfection 26/94 (27.6) 63/260 (24.2) 0.51
CD4 count ≤200 cells/mm3 20/21 (95.2) 46/51 (90.2) 0.48
Diabetes mellitus 20/94 (21.2) 60/260 (23) 0.72
Connective tissue diseasee 17/94 (18) 28/260 (10.7) 0.068
Charlson comorbidity index ≥3 46/94 (48.9) 121/260 (46.5) 0.69
Glucocorticoid usef 25/94 (26.6) 37/260 (14.2) 0.007
Symptom onset to diagnosis, days, median (IQR) 62 (35–131) 80 (33–182) 0.15g
Presenting symptoms
Fever 75/93 (80.6) 194/255 (76) 0.36
Weight loss 48/93 (51.6) 137/255 (53.7) 0.72
Cough 47/93 (50.5) 171/255 (67) 0.005
Haemoptysis 5/93 (5.3) 26/255 (10.2) 0.16
Dyspnoea 25/93 (26.8) 81/255 (31.7) 0.38
Chest radiography pattern
Normal 13/79 (16.4) 19/242 (7.8) 0.027
Cavitary 9/79 (11.3) 33/242 (13.6) 0.6
Miliary 30/79 (37.9) 63/242 (26) 0.042
Pleural effusion 17/79 (21.5) 40/242 (16.5) 0.31
Consolidation 13/79 (16.4) 65/242 (26.8) 0.061
Nodule 1/79 (1.2) 23/242 (9.5) 0.013h
Interstitial 1/79 (1.2) 10/242 (4.1) 0.3h
Respiratory sample positive smear 39/88 (44.3) 132/252 (52.3) 0.19
Data are n/N (%) of cases, unless otherwise indicated. n values across categories might be less than the counts in the column headings due to missing data
IQR Interquartile range, BCG Bacillus Calmette-Guérin, TB Tuberculosis, HIV Human immunodeficiency virus
aExcludes cases that involved extrapulmonary disease only
bp values were determined by the χ2 test
cp value was determined by Student’s t-test
dAs determined by SENASICA
eSystemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, dermatomyositis, ankylosing spondylitis, mixed connective tissue disease,
systemic sclerosis
f ≥ 15 mg/d of prednisone or equivalent dose of steroids for 1 month or more in the year prior to TB diagnosis
gp value was determined by the Mann–Whitney U test
hp values were determined by Fisher’s exact test
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test reactivity was also significantly lower amongst M.
bovis-infected patients, supporting a higher degree of
immunosuppression. The proportion of cases co-infected
with HIV included in this report was higher that the 2014
WHO reports for Mexico (9 %) [31]. However, we did not
identify an association between HIV coinfection and M.
bovis disease, even after stratification by CD4+ counts.
Similar studies from non-endemic regions have reported
contradictory results or borderline associations with HIV
[10, 11, 15]. This finding suggests that, in a high M. bovis-
burden country, the risk of TB caused by either species is
similar among people living with HIV.
The prevalence of M. bovis in humans correlates with
that of BTB. This has been established by the decrease
in prevalence after the implementation of BTB preven-
tion programs in Europe [2]. Reports from developed
countries show that most cases occur among immi-
grants. In fact, the majority of the studies conducted in
the United States have identified a connection with
Mexico [11, 15]. We and others have previously
described that close contact with cattle is an associated
factor for developing M. bovis disease [32]; in the
present study, we tried to measure this effect by identify-
ing patients who lived in non-accredited regions for BTB
eradication, but we were unable to find a significant as-
sociation. This might be explained by the geographical
location of our hospital and the fact that most of our
patients reside in the central states of Mexico, where the
highest prevalence of BTB is reported, and because
exposure-related data such as unpasteurized dairy con-
sumption and close contact with cattle were missing
from most of the clinical records [17]. Additionally,
changes in the definition of high-prevalence zones
regarding BTB have occurred through time due new re-
quirements for cattle export; therefore, we were unable
to compare this variable through the study period and
this may also have accounted for the lack of association.
We observed a higher proportion of M. tuberculosis
among patients with a lower socioeconomic status. This
may be related to conditions such as living in crowded
settings, alcoholism, and malnutrition, which may be
more critical for an exclusively airborne pathogen like
M. tuberculosis [33].
Traditionally, M. bovis has been associated with
extrapulmonary disease; however, it is unclear if this
is related to route of contagion, the immune status of
the host, or if it obeys to particular virulence features of
M. bovis [2, 14, 34]. In this study, the proportion of extra-
pulmonary disease was higher than the 2014 WHO
reports for Mexico (≈20 %), and we found a similar
proportion of patients with concurrent pulmonary and
extrapulmonary disease among both species, but a higher
proportion of M. bovis causing exclusively extrapulmonary
disease, suggesting that extrapulmonary spread is not
determined by species but may be determined by the
route of contagion.
We report a sizeable amount of pulmonary M. bovis,
which is consistent with previous reports [10, 11, 15].
The proportion of patients that reported contact with
TB-infected people was similar among both groups. This
suggests that human-to-human airborne transmission of
M. bovis may possibly contribute to the TB burden. In
fact, a previous study found a similar rate of tuberculin
skin test positivity among household contacts of patients
with M. bovis and M. tuberculosis [7]. However, we do
not have information regarding the causing species
among the contacts and this precludes us from reaching
a conclusion. Also, it is possible that contacts may share
other sources of contagion such as contact with cattle,
unpasteurized dairy products, and exposure to other TB
cases in an intermediate burden setting. We also found
smoking as an associated factor for M. bovis among pul-
monary cases. Previously, it has been reported as a risk
factor for TB because smoking causes local alterations of
the lung immune response and dysfunctional mucocili-
ary clearance [35–38]. In the case of a less airborne-
Table 4 Multivariate analysis of factors associated with Mycobacterium bovis compared with Mycobacterium tuberculosis, Mexico City,
2000–2015
All cases Pulmonary casesa
Factor Adjusted OR (95 % CI) Adjusted OR (95 % CI)
Age 0.97 (0.95–0.98) 0.97 (0.96–0.99)
Resides in non-accredited zone for bovine-TB eradicationb 1.68 (0.94–3.0) 1.67 (0.77–3.62)
Low socioeconomic status 0.52 (0.28–0.97) 0.48 (0.21–1.1)
Glucocorticoid usec 2.27 (1.42–3.63) 2.41 (1.30–4.46)
Extrapulmonary disease 1.80 (1.21–2.69) 1.61 (0.93–2.80)
Smoker (present) 1.94 (1.15–3.27)
Values were determined by logistic regression
OR Odds ratio, CI Confidence interval, TB Tuberculosis
aExcludes cases that involved extrapulmonary disease only
bAs determined by SENASICA
c ≥ 15 mg/d of prednisone or equivalent dose of steroids for 1 month or more in the year before TB diagnosis
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efficient pathogen such as M. bovis, these alterations
may be more relevant.
In the same way as in previous studies, we found simi-
lar proportions of positive direct microscopy smears and
cavitations in the CXR [7, 14]. These are considered the
most important features that determine the contagious-
ness in pulmonary TB. Therefore, we believe that
pulmonary M. bovis patients must be subject to the
same isolation measures as M. tuberculosis in order to
avoid spread. With respect to other radiographic pat-
terns in the CXR, patients with a positive culture for M.
bovis were more frequently reported without abnormal-
ities. This may indicate the need to perform more
detailed imaging studies whenever M. bovis is suspected.
We did not observe a difference regarding in-hospital
mortality between both species, even after stratification
by disease site. However, we did not perform a detailed
mortality analysis due to the lack of severity of disease
variables necessary for adjustment. Furthermore, it is
also likely that in-hospital mortality may have been over-
estimated in our study due to the overrepresentation of
immunosuppressed patients. Regarding the impact of
anti-tuberculosis treatment, it may be difficult to assess
the impact of the absence of the pyrazinamide effect on
M. bovis during the initial phase of treatment when
other drugs are administered concomitantly. However,
we believe that species identification is more critical for
relapse and treatment failure rates in the long-term,
given that the continuation phase of treatment may need
to be prolonged (as with any pyrazinamide resistant
isolate) [39]. This may be overlooked by clinicians in a
setting where susceptibility testing and/or species identi-
fication is not performed. Unfortunately, currently we
are not able to analyse long-term outcomes. Virtually all
patients are only seen in our hospital during the acute
phase of the disease, and are later followed by their local
health clinic.
This study has some limitations. The retrospective de-
sign precluded us from exploring important variables that
are subject to the quality of the original interview, includ-
ing known risk factors for M. bovis infection such as
consumption of unpasteurized dairy products and contact
with cattle. Also, the search for additional extrapulmonary
sites was not performed systematically, but rather it was
symptom oriented, and perhaps the isolation of M. bovis
may have triggered a more exhaustive search. Addition-
ally, we did not include data from children in this study
given that our hospital only tends to the adult population,
precluding us from further exploring this age group as a
risk factor. This is important because TB caused by M.
bovis has been described more frequently among children
[40]. Finally, the patient population of this tertiary
care centre may not be representative of the rest of the
country. We have a large cohort of immunosuppressed
people, and the majority of the patients reside in the cen-
tral region of the country where BTB is more prevalent.
Therefore, studies performed in the general population
are needed to further elucidate the role of BTB prevalence
as risk factor for M. bovis in humans.
Conclusions
In conclusion, younger age, glucocorticoid use, and extra-
pulmonary disease were associated with M. bovis disease
among patients of a tertiary care hospital, whereas low
socioeconomic status was associated with M. tuberculosis
disease in this same group. These differences demonstrate
that, although considered very closely related mycobac-
teria species with indistinguishable clinical presentations,
clinicians must be aware of the possibility of M. bovis in
the presence of these features in similar settings, especially
because it may be required to adjust treatment length in
the absence of pyrazinamide activity. However, further
studies in the general population with a proper follow-up
are needed to generalize these findings and define other
associated factors for M. bovis disease.
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